Welcome to Market Research Explore
MRE

Explore Market Research

Latest market research, industry analysis and market trend reports

DHF (Dengue Hemorrhagic Fever)- Market Insights, Epidemiology and Market Forecast 2028

DHF (Dengue Hemorrhagic Fever)- Market Insights, Epidemiology and Market Forecast 2028

Table of Contents 1 Key Insights 2 DHF (Dengue Hemorrhagic Fever) Market Overview at a Glance 2.1 Market Share (%) Distribution of DHF (Dengue Hemorrhagic Fever) in 2018 2.2 Market Share (%) Distribution of DHF (Dengue Hemorrhagic Fever) in 2028 3 DHF (Dengue Hemorrhagic Fever): Disease Background and Overview 3.1 Introduction 3.2 Symptoms 3.3 Etiology 3.4 Risk Factor 3.5 Pathophysiology 3.6 Diagnosis 3.7 Treatment 4 Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of DHF (Dengue Hemorrhagic Fever) in 7MM 4.3. Total Prevalent Patient Population of DHF (Dengue Hemorrhagic Fever) in 7MM – By Countries 5 Epidemiology of DHF (Dengue Hemorrhagic Fever) by Countries (2016-2028) 5.1 United States- Epidemiology (2016-2028) 5.1.1 Assumptions and Rationale 5.1.2 Prevalent/Incident Cases of DHF (Dengue Hemorrhagic Fever) in the United States 5.1.3 Sub-Type Specific cases of DHF (Dengue Hemorrhagic Fever) in the United States 5.1.4 Sex- Specific Cases of DHF (Dengue Hemorrhagic Fever) in the United States 5.1.5 Diagnosed Cases of DHF (Dengue Hemorrhagic Fever) in the United States 5.1.6 Treatable Cases of DHF (Dengue Hemorrhagic Fever) in the United States 5.2 EU5 Countries 5.2.1 Germany 5.2.1.1 Assumptions and Rationale 5.2.1.2 Prevalent/Incident Cases of the of DHF (Dengue Hemorrhagic Fever) in the Germany 5.2.1.3 Sub-Type Specific cases of DHF (Dengue Hemorrhagic Fever) in the Germany 5.2.1.4 Sex- Specific Cases of the DHF (Dengue Hemorrhagic Fever) in the Germany 5.2.1.5 Diagnosed Cases of the DHF (Dengue Hemorrhagic Fever) in the Germany 5.2.1.6 Treatable Cases of the DHF (Dengue Hemorrhagic Fever) 5.2.2 France 5.2.2.1 Assumptions and Rationale 5.2.2.2 Prevalent/Incident Cases of the of DHF (Dengue Hemorrhagic Fever) in the France 5.2.2.3 Sub-Type Specific cases of DHF (Dengue Hemorrhagic Fever) in the France 5.2.2.4 Sex- Specific Cases of the DHF (Dengue Hemorrhagic Fever) in the France 5.2.2.5 Diagnosed Cases of the DHF (Dengue Hemorrhagic Fever) in the France 5.2.2.6 Treatable Cases of the DHF (Dengue Hemorrhagic Fever) 5.2.3 Italy 5.2.3.1 Assumptions and Rationale 5.2.3.2 Prevalent/Incident Cases of the of DHF (Dengue Hemorrhagic Fever) in the Italy 5.2.3.3 Sub-Type Specific cases of DHF (Dengue Hemorrhagic Fever) in the Italy 5.2.3.4 Sex- Specific Cases of the DHF (Dengue Hemorrhagic Fever) in the Italy 5.2.3.5 Diagnosed Cases of the DHF (Dengue Hemorrhagic Fever) in the Italy 5.2.3.6 Treatable Cases of the DHF (Dengue Hemorrhagic Fever) 5.2.4 Spain 5.2.4.1 Assumptions and Rationale 5.2.4.2 Prevalent/Incident Cases of the of DHF (Dengue Hemorrhagic Fever) in the Spain 5.2.4.3 Sub-Type Specific cases of DHF (Dengue Hemorrhagic Fever) in the Spain 5.2.4.4 Sex- Specific Cases of the DHF (Dengue Hemorrhagic Fever) in the Spain 5.2.4.5 Diagnosed Cases of the DHF (Dengue Hemorrhagic Fever) in the Spain 5.2.4.6 Treatable Cases of the DHF (Dengue Hemorrhagic Fever) 5.2.5 United Kingdom 5.2.5.1 Assumptions and Rationale 5.2.5.2 Prevalent/Incident Cases of the of DHF (Dengue Hemorrhagic Fever) in the United Kingdom 5.2.5.3 Sub-Type Specific cases of DHF (Dengue Hemorrhagic Fever) in the United Kingdom 5.2.5.4 Sex- Specific Cases of the DHF (Dengue Hemorrhagic Fever) in the United Kingdom 5.2.5.5 Diagnosed Cases of the DHF (Dengue Hemorrhagic Fever) in the United Kingdom 5.2.5.6 Treatable Cases of the DHF (Dengue Hemorrhagic Fever) 5.3 Japan 5.3.1 Assumptions and Rationale 5.3.2 Prevalent/Incident Cases of the of DHF (Dengue Hemorrhagic Fever) in the Japan 5.3.3 Sub-Type Specific cases of DHF (Dengue Hemorrhagic Fever) in the Japan 5.3.4 Sex- Specific Cases of the DHF (Dengue Hemorrhagic Fever) in the Japan 5.3.5 Diagnosed Cases of the DHF (Dengue Hemorrhagic Fever) in the Japan 5.3.6 Treatable Cases of the DHF (Dengue Hemorrhagic Fever) 6 Current Treatment & Medical practices 6.1 Treatment Algorithm 6.2 Treatment Guidelines 7 Unmet Needs 8 Marketed Product 8.1 Drug A: Company 1 8.1.1 Drug Description 8.1.2 Mechanism of Action 8.1.3 Clinical Trials Details 8.1.4 Advantages & Disadvantages 8.1.5 Safety and Efficacy 8.1.6 Product Profile 8.2 Drug B: Company 2 8.2.1 Drug Description 8.2.2 Mechanism of Action 8.2.3 Clinical Trials Details 8.2.4 Advantages & Disadvantages 8.2.5 Safety and Efficacy 8.2.6 Product Profile 8.3 Drug C: Company 3 8.3.1 Drug Description 8.3.2 Mechanism of Action 8.3.3 Clinical Trials Details 8.3.4 Advantages & Disadvantages 8.3.5 Safety and Efficacy 8.3.6 Product Profile 8.4 Drug D: Company 4 8.4.1 Drug Description 8.4.2 Mechanism of Action 8.4.3 Clinical Trials Details 8.4.4 Advantages & Disadvantages 8.4.5 Safety and Efficacy 8.4.6 Product Profile 8.5 Drug E: Company 5 8.5.1 Drug Description 8.5.2 Mechanism of Action 8.5.3 Clinical Trials Details 8.5.4 Advantages & Disadvantages 8.5.5 Safety and Efficacy 8.5.6 Product Profile 8.6 : Company 6 8.6.1 Drug Description 8.6.2 Mechanism of Action 8.6.3 Clinical Trials Details 8.6.4 Advantages & Disadvantages 8.6.5 Safety and Efficacy 8.6.6 Product Profile 8.7 : Company 7 8.7.1 Drug Description 8.7.2 Mechanism of Action 8.7.3 Clinical Trials Details 8.7.4 Advantages & Disadvantages 8.7.5 Safety and Efficacy 8.7.6 Product Profile 8.8 : Company 8 8.8.1 Drug Description 8.8.2 Mechanism of Action 8.8.3 Clinical Trials Details 8.8.4 Advantages & Disadvantages 8.8.5 Safety and Efficacy 8.8.6 Product Profile 9 Emerging Drugs 9.1 Key Cross Competition 9.2 Emerging company 9.2.1 Emerging Drug A: Company 1 9.2.1.1 Other Development Activities 9.2.1.2 Clinical Development 9.2.1.3 Clinical Trials Information 9.2.1.4 Safety and Efficacy 9.2.1.5 Advantages and Disadvantages 9.2.1.6 Product Profile 9.2.2 Emerging Drug B: Company 2 9.2.2.1 Other Development Activities 9.2.2.2 Clinical Development 9.2.2.3 Clinical Trials Information 9.2.2.4 Safety and Efficacy 9.2.2.5 Advantages and Disadvantages 9.2.2.6 Product Profile 9.2.3 Emerging Drug C: Company 3 9.2.3.1 Other Development Activities 9.2.3.2 Clinical Development 9.2.3.3 Clinical Trials Information 9.2.3.4 Safety and Efficacy 9.2.3.5 Advantages and Disadvantages 9.2.3.6 Product Profile 9.2.4 Emerging Drug D: Company 4 9.2.4.1 Other Development Activities 9.2.4.2 Clinical Development 9.2.4.3 Clinical Trials Information 9.2.4.4 Safety and Efficacy 9.2.4.5 Advantages and Disadvantages 9.2.4.6 Product Profile 9.2.5 Emerging Drug E: Company 5 9.2.5.1 Other Development Activities 9.2.5.2 Clinical Development 9.2.5.3 Clinical Trials Information 9.2.5.4 Safety and Efficacy 9.2.5.5 Advantages and Disadvantages 9.2.5.6 Product Profile 10 7MM Market Analysis 10.1 7MM Market Size of DHF (Dengue Hemorrhagic Fever) 10.2 7MM Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) 10.3 7MM Market Sales of DHF (Dengue Hemorrhagic Fever) by Products 11 The United States Market Outlook 11.1 Market Size of DHF (Dengue Hemorrhagic Fever) in United States 11.2 Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) in United States 11.3 Market Sales of DHF (Dengue Hemorrhagic Fever) by Products in United States 11.4 Analysis of Upcoming Therapies and Impact on the Market 12 EU5 Countries Market Outlook 12.1 Market Size of DHF (Dengue Hemorrhagic Fever) in EU5 12.2 Market Size of DHF (Dengue Hemorrhagic Fever) in Germany 12.2.1 Market Size of DHF (Dengue Hemorrhagic Fever) in Germany 12.2.2 Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) in Germany 12.2.3 Market Sales of DHF (Dengue Hemorrhagic Fever) by Products in Germany 12.2.4 Analysis of Upcoming Therapies and Impact on the Market 12.3 Market Size of DHF (Dengue Hemorrhagic Fever) in France 12.3.1 Market Size of DHF (Dengue Hemorrhagic Fever) in France 12.3.2 Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) in France 12.3.3 Market Sales of DHF (Dengue Hemorrhagic Fever) by Products in France 12.3.4 Analysis of Upcoming Therapies and Impact on the Market 12.4 Market Size of DHF (Dengue Hemorrhagic Fever) in Italy 12.4.1 Market Size of DHF (Dengue Hemorrhagic Fever) in Italy 12.4.2 Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) in Italy 12.4.3 Market Sales of DHF (Dengue Hemorrhagic Fever) by Products in Italy 12.4.4 Analysis of Upcoming Therapies and Impact on the Market 12.5 Market Size of DHF (Dengue Hemorrhagic Fever) in Spain 12.5.1 Market Size of DHF (Dengue Hemorrhagic Fever) in Spain 12.5.2 Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) in Spain 12.5.3 Market Sales of DHF (Dengue Hemorrhagic Fever) by Products in Spain 12.5.4 Analysis of Upcoming Therapies and Impact on the Market 12.6 Market Size of DHF (Dengue Hemorrhagic Fever) in United Kingdom 12.6.1 Market Size of DHF (Dengue Hemorrhagic Fever) in United Kingdom 12.6.2 Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) in United Kingdom 12.6.3 Market Sales of DHF (Dengue Hemorrhagic Fever) by Products in United Kingdom 12.6.4 Analysis of Upcoming Therapies and Impact on the Market 13 The Japan Market Outlook 13.1 Market Size of DHF (Dengue Hemorrhagic Fever) in Japan 13.2 Percentage Share of Drugs Marketed for DHF (Dengue Hemorrhagic Fever) in Japan 13.3 Market Sales of DHF (Dengue Hemorrhagic Fever) by Products in Japan 13.4 Analysis of Upcoming Therapies and Impact on the Market 14 Cost Analysis of DHF (Dengue Hemorrhagic Fever) 15 Generic Competition in DHF (Dengue Hemorrhagic Fever) Market 16 Market Drivers 17 Market Barriers 18 Report Methodology 18.1 Methodology/Research Approach 18.2 Data Source 18.2.1 Secondary Sources 18.2.2 Primary Sources


  Payment Mode
Single User 5980
Corporate User 12980

  About this Report
Category Medical
Published on 12/20/2019
Number of Pages 136
Over all Rating
"Rating is based on 65 reviews"